Paul Sargos
A5023740879- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Sarcoma Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Advanced Radiotherapy Techniques
- Urological Disorders and Treatments
- Urologic and reproductive health conditions
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Bone Tumor Diagnosis and Treatments
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Esophageal Cancer Research and Treatment
- Radiation Therapy and Dosimetry
- Renal cell carcinoma treatment
- Cancer, Lipids, and Metabolism
- Cancer Diagnosis and Treatment
- Management of metastatic bone disease
- PARP inhibition in cancer therapy
- Colorectal and Anal Carcinomas
- Radiomics and Machine Learning in Medical Imaging
- Testicular diseases and treatments
- Effects of Radiation Exposure
- Colorectal Cancer Surgical Treatments
Institut Bergonié
2016-2025
Centre Hospitalier Universitaire de Bordeaux
2024
McGill University Health Centre
2020-2023
Radiation Oncology Institute
2023
Lymphoma Study Association
2022
McGill University
2020-2021
Jewish General Hospital
2020
Royal London Hospital
2019
University College London
2019
Centre Georges François Leclerc
2017
Purpose: This phase I study aimed to determine the recommended dose (RD), safety profile, and feasibility of a procedure combining intratumoral injection hafnium oxide nanoparticles (NBTXR3; radioenhancer) external beam radiotherapy (EBRT) for preoperative treatment adults with locally advanced soft tissue sarcoma (STS).Experimental Design: Patients had indication EBRT STS extremity or trunk. Baseline tumor volume (TV) was calculated by MRI. NBTXR3 injected percutaneously into tumors at 53.3...
LBA5000 Background: PEACE-1 demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) radiographic progression-free-survival (rPFS) in men de novo mCSPC. The present analysis examines the second pre-planned primary endpoint of low-volume population: impact prostate irradiation (RT) receiving intensified systemic treatment. Methods: is an academic, multicentre, international, 2x2 design, phase 3 trial. co-primary endpoints...
LBA259 Background: Radiotherapy (RT) delivered in combination with androgen deprivation therapy (ADT) improve survival for patients prostate adenocarcinoma. RT given at a dose of 80 Gy is generally well tolerated but the occurrence grade 3-4 toxicities significantly more frequent than 70 Gy. Furthermore, ADT has been reported to increase RT-related toxicity. Thus, we aimed evaluate efficacy and safety escalation long term high-risk cancer patients. Methods: The GETUG-AFU 18 study, sponsored...
Well-designed observational studies of individuals with rare tumors are needed to improve patient care, clinical investigations, and the education healthcare professionals.The patterns outcomes, prognostic factors a cohort 2225 patients metastatic soft tissue sarcomas who were diagnosed between 1990 2013 documented in prospectively maintained database French Sarcoma Group analyzed.The median number systemic treatments was 3 (range, 1-6); 27% did not receive any treatment 1054 (49%) underwent...
Background and purposeOligometastatic prostate cancer is a new emerging treatment field with only few prospective randomized studies published so far. Despite the lack of strong level I evidence, metastasis-directed therapies (MDT) are widely used in clinical practice, mainly based on retrospective small phase 2 large difference across centers. Pending results ongoing trials, there clear need for more consistent indications radiotherapy practices.Material methodsA European Society...
Radiotherapy is essential for locoregional control in resectable soft-tissue sarcoma (STS) and remains a key strategy unresectable STS. PARP inhibitors, such as olaparib, may enhance radiosensitivity by targeting DNA damage repair pathways. This multicenter phase 1b trial evaluated the combination of olaparib radiotherapy STS limbs or trunk wall. Olaparib was administered twice daily at doses 25, 50, 100, 150 mg during dose-escalation phase. consisted 50 Gy (25 fractions) tumors 59.4 (33...
Brain metastases (BM) from differentiated thyroid carcinoma (DTC) are uncommon, and many questions about their management remain unsolved. The objective of this retrospective study was to analyze the characteristics, treatments, outcomes patients with BM DTC.Among 1523 a DTC prospectively recorded in institutional databases between 1989 2012, 21 (1.4%) were retrospectively retrieved. Patient histological findings on initial thyroidectomy specimen, time death reviewed. Overall survival (OS)...
Local consolidative radiotherapy in the treatment of metastatic malignancies has shown promising results several types tumors. The objective this study was to assess bladder and residual metastases urothelial cancer with no progression following first-line systemic therapy.Patients who received therapy for (mUBC) were progression-free more than five retrospectively identified through database four Comprehensive Cancer Centers, between January 2005 December 2018. Among them, patients...
Desmoplastic Small Round Cell Tumor (DSRCT) is a rare disease affecting predominantly children and young adults for which the benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) after complete cytoreductive surgery (CCRS) remains unknown.To identify patients with DSRCT without extraperitoneal metastases (EPM) who underwent CCRS between 1991 2015, retrospective nation-wide survey was conducted by crossing prospective databases French Network Rare Peritoneal Malignancies, Reference in...